Determination of CSF GFAP, CCN5, and vWF Levels Enhances the Diagnostic Accuracy of Clinically Defined MS From Non-MS Patients With CSF Oligoclonal Bands.

Journal: Frontiers in immunology
PMID: 35185866

Abstract

BACKGROUND: Inclusion of cerebrospinal fluid (CSF) oligoclonal IgG bands (OCGB) in the revised McDonald criteria increases the sensitivity of diagnosis when dissemination in time (DIT) cannot be proven. While OCGB negative patients are unlikely to develop clinically definite (CD) MS, OCGB positivity may lead to an erroneous diagnosis in conditions that present similarly, such as neuromyelitis optica spectrum disorders (NMOSD) or neurosarcoidosis.

Authors

  • Fay Probert
    Department of Chemistry, University of Oxford, Oxford, United Kingdom.
  • Tianrong Yeo
    Department of Pharmacology, University of Oxford, Oxford, United Kingdom.
  • Yifan Zhou
    Department of Pharmacology, University of Oxford, Oxford, United Kingdom.
  • Megan Sealey
    Department of Pharmacology, University of Oxford, Oxford, United Kingdom.
  • Siddharth Arora
    Department of Mathematics, University of Oxford, Oxford, United Kingdom.
  • Jacqueline Palace
    Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.
  • Timothy D W Claridge
    Department of Chemistry, University of Oxford, Oxford, United Kingdom.
  • Rainer Hillenbrand
    Biomarker Development, Novartis Pharma AG, Basel, Switzerland.
  • Johanna Oechtering
    Neurologic Clinic and Policlinic, Multiple Sclerosis (MS) Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Clinical Research and Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland.
  • Jens Kuhle
    Neurologic Clinic and Policlinic, Multiple Sclerosis (MS) Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Clinical Research and Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland.
  • David Leppert
    Neurologic Clinic and Policlinic, Multiple Sclerosis (MS) Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Clinical Research and Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland.
  • Daniel C Anthony
    Department of Pharmacology, University of Oxford, Oxford, United Kingdom.

Keywords

External Resources

Popular Topics
Recent Journals